Drug intelligence / Profile preview

thiotepa + carboplatin + etoposide

Development stage: Unknown
Lead developer: Adienne S.r.l. S.U.
Modality: Small Molecules
Administration: Intravenous

Overview

A high-dose chemotherapy regimen consisting of thiotepa, carboplatin, and etoposide used primarily before autologous stem cell transplantation (ASCT) for patients with recurrent medulloblastoma and relapsed/refractory germ cell tumors. The typical administration schedule involves carboplatin on days -8 to -6, followed by thiotepa and etoposide on days -5 to -3, with autologous stem cell rescue (ASCR) on day 0. Standard dosing includes carboplatin 500 mg/m² (or AUC = 7 mg/mL × min), thiotepa 300 mg/m²/day, and etoposide 250 mg/m²/day.

Other names: thiotepa + carboplatin + etoposideTKE regimen

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on thiotepa + carboplatin + etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiotepa + carboplatin + etoposide.

Explore the full profile